Persantin 75 mg
1coated tablet contains: Dipyridamole 75mgCompany Name
CID/Boehringer
Therapeutic Group
CORON THER EX CA/ANT/NIT
Pharmaceutical form
Tablet
Package
Coated tablets of 75 mg
Indications
As an adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with mechanical prosthetic heart valves.
Warning & Precautions
- Among other properties, dipyridamole acts as a vasodilator. It should be used with caution in patients with severe coronary artery disease, including unstable angina and recent myocardial infarction,left ventricular outflow obstruction or haemodynamic instability (e.g.decompensated heart failure).patients treated with regular oral doses of PERSANTIN should not receive additional intravenous PERSANTIN. - In patients with myasthenia gravis, readjustment of therapy may be necessary after changes in dipyridamole dosage (see interaction). - A small number of cases have been reported in which unconjugated dipyridamole was shown to be incorporated into gallstones to a variable extent (up to 70%by dry weight of stone). These patients were elderly, had evidence of ascending cholangitis and had been treated with oral dipyridamole for a number of years. There is no evidence that dipyridamole was the initiating factor in causing gallstones to form in these patients. It is possible that bacterial deglucuronidation of conjugated dipyridamole in bile may be the mechanism responsible for the presence of dipyridamole in gallstones. - Pregnancy and lactation: There is inadequate evidence of safety in human pregnancy, but PERSANTIN has been used for many years without apparent ill-consequence. Preclinical studies have shown no hazard. Nevertheless, medicines should not be used in pregnancy, especially the first trimester, unless the expected benefit is thought to outweigh the possible risk to the foetus. PERSANTIN should only be used during lactation if considered essential by the physician.
Product Type
human
Dosage
A dosage range of 300-450 mg/day in divided doses is recommended. The maximum daily dose is 600 mg. There is only limited information on the use of PERSANTIN in children.
Adverse Reactions
Adverse effects at therapeutic doses are usually mild and transient: - Vomiting, diarrhoea and symptoms such as dizziness, nausea, headache and myalgia have been observed. Such effects usually disappear on long-term use of PERSANTIN. - As a result of its vasodilator properties, PERSANTIN may cause hypotension, hot flushes and tachycardia. Worsening of symptoms of coronary heart disease has been observed. - Hypersensitivity reactions such as rash, urticaria, severe bronchospasm and angio-oedema have been reported. - In very rare cases, increased bleeding during or after surgery has been observed. - Isolated cases of thrombocytopenia have been reported in conjunction with treatment with PERSANTIN. - Dipyridamole has been shown to be incorporated into gallstones (see Special Warnings and Precautions).
Contra Indications
Hypersensitivity to any of components of the product.
Drug Interactions
- Dipyridamole increase plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage should be considered. - When dipyridamole is used in combination with anticoagulants and acetylsalicylic acid, the statements on intolerance and risks for these preparations must be observed. Addition of dipyridamole to acetylsalicylic acid does not increase the incidence of bleeding events. When dipyridamole was administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. - Dipyridamole may increase the hypotensive effect of drugs which reduce blood pressure and may counteract the anticholinesterase effect of cholinesterase inhibitors thereby potentially aggravating myasthenia gravis.
No comments:
Post a Comment